3 Pages
English

Advances in Biomarker Testing Drives Cancer Management to Soon Resemble Chronic Disease Management, Finds Frost & Sullivan

Gain access to the library to view online
Learn more

Description

Advances in Biomarker Testing Drives Cancer Management to Soon Resemble Chronic Disease Management, Finds Frost & Sullivan PR Newswire MOUNTAIN VIEW, California, Sept. 25, 2012 - Health plans require clear evidence of the clinical utility of biomarker tests MOUNTAIN VIEW, California, Sept. 25, 2012 /PRNewswire/ -- With technological advances in diagnostics, physicians may shortly have real-time information about the tumor at various stages of patient management. Future cancer biomarker tests will also be multiplexed and comprise multiple biomarker types. As personalized medicine involves matching effective treatments to individuals based on their genetic disposition and other reliable factors, highly specific biomarkers are critical for identifying likely responders from non- responders. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com/) Analysis of the U.S. Cancer Biomarker Testing Market research finds that the health plan reimbursement market earned revenues of $7.86 billion in 2011 and estimates this to reach $11.46 billion in 2017. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Subjects

Informations

Published by
Reads 11
Language English
Advances in Biomarker Testing Drives Cancer Management to Soon Resemble Chronic Disease Management, Finds Frost & Sullivan
PR Newswire MOUNTAIN VIEW, California, Sept. 25, 2012
- Health plans require clear evidence of the clinical utility of biomarker tests MOUNTAIN VIEW, California,Sept. 25, 2012/PRNewswire/ -- With technological advances in diagnostics, physicians may shortly have real-time information about the tumor at various stages of patient management. Future cancer biomarker tests will also be multiplexed and comprise multiple biomarker types. Aspersonalized medicine involves matching effective treatments to individuals based on their genetic disposition and other reliable factors, highly specific biomarkers are critical for identifying likely responders from non-responders. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com/) Analysis of the U.S. Cancer Biomarker Testing Marketresearch finds that the health plan reimbursement market earned revenues of$7.86 billionin 2011 and estimates this to reach$11.46 billionin 2017. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country. "Effective cancer patient management relies on specific and useful biomarkers that enable oncologists to diagnose, determine suitable therapies, continuously monitor response to therapy, or monitor tumor progression," said Frost & Sullivan Industry Analyst Winny Tan, Ph.D. "Consequently, personalized medicine is becoming a mainstream concept and the approaches to personalized medicine are increasingly understood by physicians and patients." Market participants are gearing up for exciting times in the market, as generation sequencing becomes more affordable and cost competitive with the prices of current tests that look at a single-mutation. Additionally, the accelerated trend of out-licensing and therapy-companion diagnostic co-development across the industry is likely to raise the number of new cancer biomarker tests entering the market. These new tests will be highly complex to perform and interpret. Following this, cancer testing will become centralized and more cancer biomarker tests are likely to be commercialized from multi-center research consortiums. Furthermore, the large number and variety of industry partnerships suggest that collaboration is vital to compete in the market. Companies could partner with each other for companion diagnostic development, licensing agreements, clinical trial collaboration, R&D collaborations, distribution agreements, and other commercialization interests. While technology is advancing cancer patient management, it is also escalating the costs of cancer biomarker testing. Currently, new detection platforms such as next-generation sequencing are still more expensive than traditional slide-